Specify a stock or a cryptocurrency in the search bar to get a summary
Lucid Diagnostics Inc
LUCDLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc. Address: 360 Madison Avenue, New York, NY, United States, 10017
Analytics
WallStreet Target Price
3.71 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LUCD
Dividend Analytics LUCD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LUCD
Stock Valuation LUCD
Financials LUCD
Results | 2019 | Dynamics |